Murepavadin: complete guide

Murepavadin (POL7080) is an investigational peptidomimetic antibiotic aimed at Pseudomonas aeruginosa. This guide covers its structure, target, trials, safety and status.

Complete guide5 min read

Key takeaway

Murepavadin has a molecular weight of 1,553.8 g/mol. It binds LptD, a protein that moves lipopolysaccharide to the outer surface of Pseudomonas. In July 2019, its developer Polyphor closed both Phase 3 pneumonia trials over a higher than expected frequency of acute kidney injury.

At a glance

Article typeComplete guide
Regulatory statusNot FDA-approved“Murepavadin is not approved by the FDA for any use.” (this article)
ClassImmune & inflammation
Body systemsImmune system
Studies cited5 in this article · 5 across 1 article on Murepavadin
Related productsBPC-157, TB-500 and thymic peptides

Murepavadin is a ring-shaped synthetic peptidomimetic antibiotic designed to kill only Pseudomonas aeruginosa. A 2018 review called it the first of its class. Its Phase 3 trials were closed in 2019 over kidney safety. This guide covers its structure, target, trials and status. Sources were checked on November 17, 2026.

Quick answer: Murepavadin, also called POL7080, is a macrocyclic peptidomimetic from a family based on the antimicrobial peptide protegrin I. It targets the outer membrane protein LptD of P. aeruginosa. Phase 3 trials in hospital pneumonia were closed in 2019. It is not FDA-approved.

Vitrapep does not sell murepavadin; this page is a reference summary of published research and regulatory information.

What is murepavadin?

Murepavadin is one of a family of “macrocyclic peptidomimetics” (Andolina et al., 2018). A macrocycle is a large ring. A peptidomimetic is a molecule built from peptide-like units to copy a natural peptide’s shape. Our guide to types of peptides covers cyclic peptides and mimetics.

The family began with antibiotics “based on the antimicrobial peptide protegrin I,” a host defense peptide (Srinivas et al., 2010). A 2018 review calls murepavadin a “pathogen specific antimicrobial peptidomimetic.” It also calls it “the first in class of outer membrane protein targeting antibiotics” (Martin-Loeches et al., 2018).

PubChem lists the formula as C73H112N22O16 and the molecular weight as 1,553.8 g/mol (PubChem CID 91824766). Its research code was POL7080.

Table 1

Murepavadin: key facts

Fact Detail
Structure type Macrocyclic (ring-shaped) peptidomimetic
Class Outer membrane protein targeting antibiotic (LptD binder)
Molecular formula C73H112N22O16
Molecular weight 1,553.8 g/mol
Development stage Phase 3 pneumonia trials closed (2019); Phase 1 of a second formulation, iMPV, completed (reported 2023)
Sponsor or developer Polyphor (Switzerland); later work by Spexis AG

How does murepavadin work?

Most membrane-active peptides punch holes in bacteria. This family does not. The 2010 study described a “non-membrane-lytic mechanism of action.” It identified the outer membrane protein LptD as a target in Pseudomonas (Srinivas et al., 2010). The lead compound was active against Pseudomonas but “largely inactive against other Gram-negative and Gram-positive bacteria.”

LptD, with its partner LptE, moves lipopolysaccharide (LPS) to the outer surface of the cell. A 2018 lab study found that murepavadin “cross-links to the periplasmic segment of LptD.” The authors expected this binding to block LPS transport (Andolina et al., 2018). They note that the LPS transport pathway is essential in many Gram-negative bacteria.

What is murepavadin being studied for?

Murepavadin is not approved by the FDA for any use. ClinicalTrials.gov lists six Polyphor studies. None is recruiting.

  • ventilator-associated P. aeruginosa pneumonia, Phase 2, 25 enrolled (NCT02096328, completed 2016);
  • flare-ups of non-cystic fibrosis bronchiectasis, Phase 2 (NCT02096315, terminated 2015);
  • ventilator-associated pneumonia, Phase 3, 41 enrolled (NCT03409679, terminated 2019); and
  • hospital-acquired pneumonia, Phase 3, 2 enrolled (NCT03582007, terminated 2019).

Both Phase 3 records give the reason for stopping as “Safety data review.” Two Phase 1 studies covered kidney impairment and a drug interaction with amikacin. A later program studied a second formulation, called iMPV. Its UK Phase 1 in healthy volunteers was sponsored by Spexis AG (NHS Health Research Authority, 2020).

What did the key trials show?

Discovery work. The 2010 study tested an early family member, not murepavadin itself. It showed potent activity in a mouse septicemia model, plus biochemical and genetic target work (Srinivas et al., 2010).

Phase 1 in healthy adults. This human study enrolled healthy adults. The authors reported that “murepavadin was well tolerated” and that no limiting toxicity was found (Wach et al., 2018).

Phase 3 PRISM trials. No results are posted on ClinicalTrials.gov for any murepavadin study. We found no peer-reviewed report of the Phase 2 or Phase 3 pneumonia trials. Polyphor stated it closed both Phase 3 studies in July 2019 (Polyphor, 2019).

What side effects have studies reported?

In healthy volunteers, adverse events were described as “transient and generally mild” (Wach et al., 2018). In patients, the key signal was kidney injury. Polyphor cited “a higher than expected frequency of acute kidney injury” in Phase 3, based on rising serum creatinine. It said the decision did not affect its second formulation program.

For iMPV, Spexis reported completing a first-in-human trial in 39 subjects (Spexis, 2023). We found no peer-reviewed safety report from that trial.

What is murepavadin’s regulatory status, and how is it used in research?

Murepavadin is an investigational antibiotic. In April 2019, Polyphor said FDA had designated it a Qualified Infectious Disease Product (QIDP) in four more indications. It already held QIDP status for ventilator-associated bacterial pneumonia (Polyphor, 2019). We found no FDA warning about it. In January 2023, Spexis said its Phase 1 result “clears the way” for trials in cystic fibrosis or bronchiectasis. We found no such trial registered on ClinicalTrials.gov.

In the lab, murepavadin is a tool for studying LPS transport and resistance in Pseudomonas. One study found strains resistant to it carried mutations in the sensor gene pmrB. The authors said this supports “a resistance mechanism shared with colistin” (Romano et al., 2019). Our polymyxin B and colistin guide covers that older drug class.

Frequently asked questions about murepavadin

Is murepavadin a peptide?

It is a macrocyclic peptidomimetic: a ring of peptide-like units designed to copy a natural antimicrobial peptide’s shape.

Is murepavadin FDA-approved?

No. Its Phase 3 trials were closed in 2019, and no approval exists.

Why were the Phase 3 trials stopped?

Polyphor cited a higher than expected frequency of acute kidney injury in patients.

Why does murepavadin act only on Pseudomonas?

Its target, LptD, has a region characteristic of Pseudomonas species. The 2018 binding study links this to its narrow spectrum.

What is POL7080?

POL7080 is Polyphor’s research code for murepavadin.

What to know now

  • Structure: macrocyclic peptidomimetic; C73H112N22O16; 1,553.8 g/mol.
  • Target: LptD, the outer membrane LPS transporter of P. aeruginosa.
  • Evidence: no published efficacy results from Phase 2 or Phase 3.
  • Safety: Phase 3 closed in July 2019 over acute kidney injury.
  • Status: not FDA-approved; QIDP designations per Polyphor; no active registered trial.

What we’re watching

Any new trial of iMPV in cystic fibrosis or bronchiectasis. Published results from the terminated PRISM trials. Related guides: brilacidin and LL-37.

More for immune system

All 24 compounds for immune system

Sources: National Center for Biotechnology Information 2026, PubChem compound summary for CID 91824766, murepavadin; Srinivas 2010, Pseudomonas aeruginosa; Andolina 2018, Pseudomonas aeruginosa; Martin-Loeches 2018, Expert Review of Anti-infective Therapy, 16; Wach 2018, Antimicrobial Agents and Chemotherapy, 62; Romano 2019, Pseudomonas aeruginosa; Polyphor Ltd 2018, Pivotal study in VAP suspected or confirmed to be due to Pseudomonas aeruginosa; Polyphor Ltd 2018, Pivotal study in nosocomial pneumonia suspected or confirmed to be due to Pseudomonas; Polyphor Ltd 2014; Polyphor Ltd 2014; Polyphor AG 2019; Polyphor 2019; NHS Health Research Authority 2020, Safety tolerability & PK study of inhaled murepavadin in healthy subjects; Spexis AG 2023. All 14 citations

Back to the research library

References

  1. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 91824766, murepavadin. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/91824766
  2. Srinivas, N., et al. (2010). Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science, 327(5968), 1010-1013. https://doi.org/10.1126/science.1182749
  3. Andolina, G., et al. (2018). A peptidomimetic antibiotic interacts with the periplasmic domain of LptD from Pseudomonas aeruginosa. ACS Chemical Biology, 13(3), 666-675. https://doi.org/10.1021/acschembio.7b00822
  4. Martin-Loeches, I., Dale, G. E., & Torres, A. (2018). Murepavadin: A new antibiotic class in the pipeline. Expert Review of Anti-infective Therapy, 16(4), 259-268. https://doi.org/10.1080/14787210.2018.1441024
  5. Wach, A., Dembowsky, K., & Dale, G. E. (2018). Pharmacokinetics and safety of intravenous murepavadin infusion in healthy adult subjects administered single and multiple ascending doses. Antimicrobial Agents and Chemotherapy, 62(4), e02355-17. https://doi.org/10.1128/AAC.02355-17
  6. Romano, K. P., et al. (2019). Mutations in pmrB confer cross-resistance between the LptD inhibitor POL7080 and colistin in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 63(9), e00511-19. https://doi.org/10.1128/AAC.00511-19
  7. Polyphor Ltd. (2018). Pivotal study in VAP suspected or confirmed to be due to Pseudomonas aeruginosa (ClinicalTrials.gov ID NCT03409679). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03409679
  8. Polyphor Ltd. (2018). Pivotal study in nosocomial pneumonia suspected or confirmed to be due to Pseudomonas (ClinicalTrials.gov ID NCT03582007). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03582007
  9. Polyphor Ltd. (2014). Pharmacokinetics, safety and efficacy of POL7080 in patients with ventilator associated Pseudomonas aeruginosa pneumonia (ClinicalTrials.gov ID NCT02096328). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02096328
  10. Polyphor Ltd. (2014). Safety, efficacy and PK/PD of POL7080 in patients with exacerbation of non-cystic fibrosis bronchiectasis (ClinicalTrials.gov ID NCT02096315). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02096315
  11. Polyphor AG. (2019, April 14). Polyphor’s antibiotic murepavadin receives US FDA Qualified Infectious Disease Product designation in four new indications [Press release]. BioSpace. https://www.biospace.com/polyphor-s-antibiotic-murepavadin-receives-us-fda-qualified-infectious-disease-product-designation-in-four-new-indications
  12. Polyphor. (2019, July 17). Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options [Press release]. BioSpace. https://www.biospace.com/polyphor-closes-the-phase-iii-prism-studies-of-murepavadin-intravenous-formulation-and-evaluates-further-product-improvement-options
  13. NHS Health Research Authority. (2020). Safety tolerability & PK study of inhaled murepavadin in healthy subjects (research summary; EudraCT 2020-004188-23). Retrieved November 17, 2026, from https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/safety-tolerability-pk-study-of-inhaled-murepavadin-in-healthy-subj
  14. Spexis AG. (2023, January 9). Spexis reports solid safety and pharmacokinetics results from first in human study with inhaled murepavadin, a novel macrocycle compound [Press release]. BEAM Alliance. https://beam-alliance.eu/spexis-reports-solid-safety-and-pharmacokinetics-results-from-first-in-human-study-with-inhaled-murepavadin-a-novel-macrocycle-compound